ArticleBiochemistry and biophysics reports2020

Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51.

Jing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.